NCT06349837View on ClinicalTrials.gov

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients with Bulky Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2026

Conditions
Solid Tumor
Interventions
DRUG

Tislelizumab

Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.

RADIATION

Low Dose Radiotherapy

LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.

RADIATION

Stereotactic Ablative Radiotherapy

Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER